BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 34304950)

  • 1. Changes in methadone take-home dosing before and after COVID-19.
    Amram O; Amiri S; Thorn EL; Lutz R; Joudrey PJ
    J Subst Abuse Treat; 2022 Feb; 133():108552. PubMed ID: 34304950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Opioid use and COVID-19: a secondary analysis of the impact of relaxation of methadone take-home dosing guidelines on use of illicit opioids.
    Panwala V; Thorn E; Amiri S; Socias ME; Lutz R; Amram O
    Am J Drug Alcohol Abuse; 2023 Sep; 49(5):597-605. PubMed ID: 37433122
    [No Abstract]   [Full Text] [Related]  

  • 3. The impact of relaxation of methadone take-home protocols on treatment outcomes in the COVID-19 era.
    Amram O; Amiri S; Panwala V; Lutz R; Joudrey PJ; Socias E
    Am J Drug Alcohol Abuse; 2021 Nov; 47(6):722-729. PubMed ID: 34670453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. COVID-19-related policy changes for methadone take-home dosing: A multistate survey of opioid treatment program leadership.
    Levander XA; Pytell JD; Stoller KB; Korthuis PT; Chander G
    Subst Abus; 2022; 43(1):633-639. PubMed ID: 34666636
    [No Abstract]   [Full Text] [Related]  

  • 5. Take-home dosing experiences among persons receiving methadone maintenance treatment during COVID-19.
    Figgatt MC; Salazar Z; Day E; Vincent L; Dasgupta N
    J Subst Abuse Treat; 2021 Apr; 123():108276. PubMed ID: 33612201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss, liberation, and agency: Patient experiences of methadone treatment at opioid treatment programs during the COVID-19 pandemic.
    López-Castro T; Jakubowski A; Masyukova M; Peterson M; Pierz A; Kodali S; Arnsten JH; Starrels JL; Nahvi S
    J Subst Use Addict Treat; 2024 Feb; 157():209235. PubMed ID: 38061636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adoption of methadone take home policy by U.S. state opioid treatment authorities during COVID-19.
    Roy V; Buonora M; Simon C; Dooling B; Joudrey P
    Int J Drug Policy; 2024 Feb; 124():104302. PubMed ID: 38183861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in methadone program practices and fatal methadone overdose rates in Connecticut during COVID-19.
    Brothers S; Viera A; Heimer R
    J Subst Abuse Treat; 2021 Dec; 131():108449. PubMed ID: 34098303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment retention, return to use, and recovery support following COVID-19 relaxation of methadone take-home dosing in two rural opioid treatment programs: A mixed methods analysis.
    Hoffman KA; Foot C; Levander XA; Cook R; Terashima JP; McIlveen JW; Korthuis PT; McCarty D
    J Subst Abuse Treat; 2022 Oct; 141():108801. PubMed ID: 35589443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acceptability, feasibility, and outcomes of a clinical pilot program for video observation of methadone take-home dosing during the COVID-19 pandemic.
    Hallgren KA; Darnton J; Soth S; Blalock KL; Michaels A; Grekin P; Saxon AJ; Woolworth S; Tsui JI
    J Subst Abuse Treat; 2022 Dec; 143():108896. PubMed ID: 36215911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Did drug use increase following COVID-19 relaxation of methadone take-out regulations? 2020 was a complicated year.
    Bart G; Wastvedt S; Hodges JS; Rosenthal R
    J Subst Abuse Treat; 2022 Feb; 133():108590. PubMed ID: 34373169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rural opioid treatment program patient perspectives on take-home methadone policy changes during COVID-19: a qualitative thematic analysis.
    Levander XA; Hoffman KA; McIlveen JW; McCarty D; Terashima JP; Korthuis PT
    Addict Sci Clin Pract; 2021 Dec; 16(1):72. PubMed ID: 34895346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COVID-19-related flexibility in methadone take-home doses associated with decreased attrition: Report from an opioid treatment program in central Pennsylvania.
    Kawasaki SS; Zimmerman R; Shen C; Zgierska AE
    J Subst Use Addict Treat; 2023 Dec; 155():209164. PubMed ID: 37730014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment provider perceptions of take-home methadone regulation before and during COVID-19.
    Madden EF; Christian BT; Lagisetty PA; Ray BR; Sulzer SH
    Drug Alcohol Depend; 2021 Nov; 228():109100. PubMed ID: 34600251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experience of patients on methadone maintenance treatment receiving take-home methadone doses during COVID-19 pandemic: A multi-site study from India.
    Kathiresan P; Patel V; Jangra J; Chattopadhyay A; Abdus S; Jadhav M; Rao R; Arya A; Bansal PD; Chinggouman C; Bhad R; Ambekar A; Agrawal A; Chatterjee B; Yadav D
    Asian J Psychiatr; 2024 May; 95():103979. PubMed ID: 38442535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Technology-assisted methadone take-home dosing for dispensing methadone to persons with opioid use disorder during the Covid-19 pandemic.
    Dunn KE; Brooner RK; Stoller KB
    J Subst Abuse Treat; 2021 Feb; 121():108197. PubMed ID: 33357606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of COVID-19-related methadone regulatory flexibilities: views of state opioid treatment authorities and program staff.
    Mitchell SG; Jester J; Gryczynski J; Whitter M; Fuller D; Halsted C; Schwartz RP
    Addict Sci Clin Pract; 2023 Oct; 18(1):61. PubMed ID: 37848970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. "The idea is to help people achieve greater success and liberty": A qualitative study of expanded methadone take-home access in opioid use disorder treatment.
    Suen LW; Castellanos S; Joshi N; Satterwhite S; Knight KR
    Subst Abus; 2022; 43(1):1143-1150. PubMed ID: 35499469
    [No Abstract]   [Full Text] [Related]  

  • 19. Impact of the COVID-19 pandemic on the provision of take-home doses of opioid agonist therapy in Ontario, Canada: A population-based time-series analysis.
    Kitchen SA; Campbell TJ; Men S; Bozinoff N; Tadrous M; Antoniou T; Wyman J; Werb D; Munro C; Gomes T
    Int J Drug Policy; 2022 May; 103():103644. PubMed ID: 35272107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased flexibility in methadone take-home scheduling during the COVID-19 pandemic: Should this practice be incorporated into routine clinical care?
    Trujols J; Larrabeiti A; Sànchez O; Madrid M; De Andrés S; Duran-Sindreu S
    J Subst Abuse Treat; 2020 Dec; 119():108154. PubMed ID: 33032860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.